Search

Your search keyword '"Staebler, Annette"' showing total 278 results
Start Over Author "Staebler, Annette" Language english
278 results on '"Staebler, Annette"'

1. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations

Author

Armbruster, Hannes, Schotte, Tilman, Götting, Isabell, Overkamp, Mathis, Granai, Massimo, Volmer, Lea Louise, Bahlinger, Veronika, Matovina, Sabine, Koch, André, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D., Brucker, Sara Y., Bonzheim, Irina, Fend, Falko, Staebler, Annette, and Montes-Mojarro, Ivonne

Published
2024
Full Text
View/download PDF

4. Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse

Author

Mittelstadt, Suzana, Kelemen, Olga, Admard, Jakob, Gschwind, Axel, Koch, André, Wörz, Sarah, Oberlechner, Ernst, Engler, Tobias, Bonzheim, Irina, Staebler, Annette, Weidner, Nicola, Stubenrauch, Frank, Iftner, Thomas, Riess, Olaf, Schroeder, Christopher, Kommoss, Stefan, and Ossowski, Stephan

Published
2023
Full Text
View/download PDF

6. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Author

Weir, Ashley, Kang, Eun-Young, Meagher, Nicola S., Nelson, Gregg S., Ghatage, Prafull, Lee, Cheng-Han, Riggan, Marjorie J., Gentry-Maharaj, Aleksandra, Ryan, Andy, Singh, Naveena, Widschwendter, Martin, Alsop, Jennifer, Anglesio, Michael S., Beckmann, Matthias W., Berger, Jessica, Bisinotto, Christiani, Boros, Jessica, Brand, Alison H., Brenton, James D., Brooks-Wilson, Angela, Carney, Michael E., Cunningham, Julie M., Cushing-Haugen, Kara L., Cybulski, Cezary, Elishaev, Esther, Erber, Ramona, Fereday, Sian, Fischer, Anna, Paz-Ares, Luis, Gayarre, Javier, Gilks, Blake C., Grube, Marcel, Harnett, Paul R., Harris, Holly R., Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y., Heublein, Sabine, Huang, Yajue, Huzarski, Tomasz, Jakubowska, Anna, Jimenez-Linan, Mercedes, Kennedy, Catherine J., Kommoss, Felix K. F., Koziak, Jennifer M., Kraemer, Bernhard, Le, Nhu D., Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Menkiszak, Janusz, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Robles-Díaz, Luis, Ruebner, Matthias, Shah, Mitul, Sharma, Raghwa, Shvetsov, Yurii B., Steed, Helen, Talhouk, Aline, Taylor, Sarah E., Traficante, Nadia, Vierkant, Robert A., Wang, Chen, Wilkens, Lynne R., Winham, Stacey J., Benitez, Javier, Berchuck, Andrew, Bowtell, David D., Candido dos Reis, Francisco J., Cook, Linda S., DeFazio, Anna, Doherty, Jennifer A., Fasching, Peter A., García, María J., Goode, Ellen L., Goodman, Marc T., Gronwald, Jacek, Huntsman, David G., Karlan, Beth Y., Kommoss, Stefan, Modugno, Francesmary, Schildkraut, Joellen M., Sinn, Hans-Peter, Staebler, Annette, Kelemen, Linda E., Ford, Caroline E., Menon, Usha, Pharoah, Paul D. P., Köbel, Martin, and Ramus, Susan J.

Published
2023
Full Text
View/download PDF

7. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Author

Kang, Eun Young, Millstein, Joshua, Popovic, Gordana, Meagher, Nicola S., Bolithon, Adelyn, Talhouk, Aline, Chiu, Derek S., Anglesio, Michael S., Leung, Betty, Tang, Katrina, Lambie, Neil, Pavanello, Marina, Da-anoy, Annalyn, Lambrechts, Diether, Loverix, Liselore, Olbrecht, Siel, Bisinotto, Christiani, Garcia-Donas, Jesus, Ruiz-Llorente, Sergio, Yagüe-Fernandez, Monica, Edwards, Robert P., Elishaev, Esther, Olawaiye, Alexander, Taylor, Sarah, Ataseven, Beyhan, du Bois, Andreas, Harter, Philipp, Lester, Jenny, Høgdall, Claus K., Armasu, Sebastian M., Huang, Yajue, Vierkant, Robert A., Wang, Chen, Winham, Stacey J., Heublein, Sabine, Kommoss, Felix K. F., Cramer, Daniel W., Sasamoto, Naoko, van-Wagensveld, Lilian, Lycke, Maria, Mateoiu, Constantina, Joseph, Janine, Pike, Malcolm C., Odunsi, Kunle, Tseng, Chiu-Chen, Pearce, Celeste L., Bilic, Sanela, Conrads, Thomas P., Hartmann, Arndt, Hein, Alexander, Jones, Michael E., Leung, Yee, Beckmann, Matthias W., Ruebner, Matthias, Schoemaker, Minouk J., Terry, Kathryn L., El-Bahrawy, Mona A., Coulson, Penny, Etter, John L., LaVigne-Mager, Katherine, Andress, Juergen, Grube, Marcel, Fischer, Anna, Neudeck, Nina, Robertson, Greg, Farrell, Rhonda, Barlow, Ellen, Quinn, Carmel, Hettiaratchi, Anusha, Casablanca, Yovanni, Erber, Ramona, Stewart, Colin J. R., Tan, Adeline, Yu, Yu, Boros, Jessica, Brand, Alison H., Harnett, Paul R., Kennedy, Catherine J., Nevins, Nikilyn, Morgan, Terry, Fasching, Peter A., Vergote, Ignace, Swerdlow, Anthony J., Candido dos Reis, Francisco J., Maxwell, G. Larry, Neuhausen, Susan L., Barquin-Garcia, Arantzazu, Modugno, Francesmary, Moysich, Kirsten B., Crowe, Philip J., Hirasawa, Akira, Heitz, Florian, Karlan, Beth Y., Goode, Ellen L., Sinn, Peter, Horlings, Hugo M., Høgdall, Estrid, Sundfeldt, Karin, Kommoss, Stefan, Staebler, Annette, Wu, Anna H., Cohen, Paul A., DeFazio, Anna, Lee, Cheng-Han, Steed, Helen, Le, Nhu D., Gayther, Simon A., Lawrenson, Kate, Pharoah, Paul D. P., Konecny, Gottfried, Cook, Linda S., Ramus, Susan J., Kelemen, Linda E., and Köbel, Martin

Published
2022
Full Text
View/download PDF

9. The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group

Author

Hasenburg, Annette, Plett, Hellmut, Krämer, Bernhard, Braicu, Elena, Czogalla, Bastian, Bossart, Michaela, Singer, Susanne, Mayr, Doris, Staebler, Annette, du Bois, Andreas, Kommoss, Stefan, Link, Theresa, Burges, Alexander, Heitz, Florian, Keul, Jacqueline, Trillsch, Fabian, Harter, Philipp, Wimberger, Pauline, Buderath, Paul, and Klar, Maximilian

Published
2021
Full Text
View/download PDF

10. Prognostic Significance of Disseminated Tumor Cells in Bone Marrow for Endometrial Carcinoma Patients.

Author

Volmer, Léa Louise, Grube, Marcel, Rohner, Annika, McAlpine, Jessica Nell, Talhouk, Aline, Lum, Amy, Matovina, Sabine, Kommoss, Stefan, Staebler, Annette, Brucker, Sara Yvonne, and Walter, Christina Barbara

Subjects
BONE marrow cancer, WOMEN'S hospitals, BONE marrow cells, NOSOLOGY, ENDOMETRIAL cancer
Abstract

Background: Until now, limited clinical significance had been reported for disseminated tumor cells (DTCs) in gynecologic malignancies. DTCs were previously reported not to be associated with established risk factors, L1CAM immunoreactivity, and outcome in endometrial carcinoma (EC). This study's primary objective was to investigate potential correlations of DTCs in the bone marrow (BM) of EC patients with disease-related survival, and a secondary objective was to evaluate associations between molecular classification of EC and DTCs. Methods: Patients treated for primary EC at Tuebingen University women's hospital between 2003 and 2016 were identified. A total of 402 patients with a complete set of BM cytology, molecular, and clinical data were evaluable. Results: DTC occurrence was distributed equally among all four molecular groups (p = 0.651). DTC positivity was associated with a less favorable disease-free survival (HR: 1.86, 95% CI: 1.03–3.36, p = 0.036) and progression-free survival (HR: 1.86, 95% CI: 1.01–3.44, p = 0.045). Presence of DTCs was associated with a higher frequency of distant disease recurrence (p = 0.017). Conclusions: In line with our previous findings, tumor cell dissemination is not associated with molecular features in our large cohort of primary EC patients. Since DTCs seem to be associated with survival and location of disease recurrence, further studies are needed to decisively define their role in EC survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

Author

Martins, Filipe Correia, Couturier, Dominique-Laurent, Paterson, Anna, Karnezis, Anthony N., Chow, Christine, Nazeran, Tayyebeh M., Odunsi, Adekunle, Gentry-Maharaj, Aleksandra, Vrvilo, Aleksandra, Hein, Alexander, Talhouk, Aline, Osorio, Ana, Hartkopf, Andreas D., Brooks-Wilson, Angela, DeFazio, Anna, Fischer, Anna, Hartmann, Arndt, Hernandez, Brenda Y., McCauley, Bryan M., Karpinskyj, Chloe, de Sousa, Christiani B., Høgdall, Claus, Tiezzi, Daniel G., Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Keeney, Gary, Nelson, Gregg, Steed, Helen, Song, Honglin, Luk, Hugh, Benitez, Javier, Alsop, Jennifer, Koziak, Jennifer M., Lester, Jenny, Rothstein, Joseph H., de Andrade, Jurandyr M., Lundvall, Lene, Paz-Ares, Luis, Robles-Díaz, Luis, Wilkens, Lynne R., Garcia, Maria J., Intermaggio, Maria P., Alcaraz, Marie-Lyne, Brett, Mary A., Beckmann, Matthias W., Jimenez-Linan, Mercedes, Anglesio, Michael, Carney, Michael E., Schneider, Michael, Traficante, Nadia, Pejovic, Nadja, Singh, Naveena, Le, Nhu, Sinn, Peter, Ghatage, Prafull, Erber, Ramona, Edwards, Robert, Vierkant, Robert, Ness, Roberta B., Leung, Samuel, Orsulic, Sandra, Brucker, Sara Y., Kaufmann, Scott H., Fereday, Sian, Gayther, Simon, Winham, Stacey J., Kommoss, Stefan, Pejovic, Tanja, Longacre, Teri A., McGuire, Valerie, Rhenius, Valerie, Sieh, Weiva, Shvetsov, Yurii B., Whittemore, Alice S., Staebler, Annette, Karlan, Beth Y., Rodriguez-Antona, Cristina, Bowtell, David D., Goode, Ellen L., Høgdall, Estrid, Candido dos Reis, Francisco J., Gronwald, Jacek, Chang-Claude, Jenny, Moysich, Kirsten B., Kelemen, Linda E., Cook, Linda S., Goodman, Marc T., Fasching, Peter A., Crawford, Robin, Deen, Suha, Menon, Usha, Huntsman, David G., Köbel, Martin, Ramus, Susan J., Pharoah, Paul D. P., and Brenton, James D.

Published
2020
Full Text
View/download PDF

13. Rel Family Transcription Factor NFAT5 Upregulates COX2 via HIF-1α Activity in Ishikawa and HEC1a Cells.

Author

Okumura, Toshiyuki, Raja Xavier, Janet P., Pasternak, Jana, Yang, Zhiqi, Hang, Cao, Nosirov, Bakhtiyor, Singh, Yogesh, Admard, Jakob, Brucker, Sara Y., Kommoss, Stefan, Takeda, Satoru, Staebler, Annette, Lang, Florian, and Salker, Madhuri S.

Subjects
TRANSCRIPTION factors, PROSTAGLANDIN receptors, CYCLOOXYGENASE 2, ENDOMETRIAL cancer, ENDOMETRIAL tumors, CANCER invasiveness
Abstract

Nuclear factor of activated T cells 5 (NFAT5) and cyclooxygenase 2 (COX2; PTGS2) both participate in diverse pathologies including cancer progression. However, the biological role of the NFAT5-COX2 signaling pathway in human endometrial cancer has remained elusive. The present study explored whether NFAT5 is expressed in endometrial tumors and if NFAT5 participates in cancer progression. To gain insights into the underlying mechanisms, NFAT5 protein abundance in endometrial cancer tissue was visualized by immunohistochemistry and endometrial cancer cells (Ishikawa and HEC1a) were transfected with NFAT5 or with an empty plasmid. As a result, NFAT5 expression is more abundant in high-grade than in low-grade endometrial cancer tissue. RNA sequencing analysis of NFAT5 overexpression in Ishikawa cells upregulated 37 genes and downregulated 20 genes. Genes affected included cyclooxygenase 2 and hypoxia inducible factor 1α (HIF1A). NFAT5 transfection and/or treatment with HIF-1α stabilizer exerted a strong stimulating effect on HIF-1α promoter activity as well as COX2 expression level and prostaglandin E2 receptor (PGE2) levels. Our findings suggest that activation of NFAT5—HIF-1α—COX2 axis could promote endometrial cancer progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. TERT promoter mutation in adult granulosa cell tumor of the ovary

Author

Pilsworth, Jessica A., Cochrane, Dawn R., Xia, Zhouchunyang, Aubert, Geraldine, Färkkilä, Anniina E.M., Horlings, Hugo M., Yanagida, Satoshi, Yang, Winnie, Lim, Jamie L.P., Wang, Yi Kan, Bashashati, Ali, Keul, Jacqueline, Wong, Adele, Norris, Kevin, Brucker, Sara Y., Taran, Florin-Andrei, Krämer, Bernhard, Staebler, Annette, van Meurs, Hannah, Oliva, Esther, Shah, Sohrab P., Kommoss, Stefan, Kommoss, Friedrich, Gilks, C. Blake, Baird, Duncan M., and Huntsman, David G.

Published
2018
Full Text
View/download PDF

17. The immunopeptidomic landscape of ovarian carcinomas

Author

Schuster, Heiko, Peper, Janet K., Bösmüller, Hans-Christian, Röhle, Kevin, Backert, Linus, Bilich, Tatjana, Ney, Britta, Löffler, Markus W., Kowalewski, Daniel J., Trautwein, Nico, Rabsteyn, Armin, Engler, Tobias, Braun, Sabine, Haen, Sebastian P., Walz, Juliane S., Schmid-Horch, Barbara, Brucker, Sara Y., Wallwiener, Diethelm, Kohlbacher, Oliver, Fend, Falko, Rammensee, Hans-Georg, Stevanovic, Stefan, Staebler, Annette, and Wagner, Philipp

Published
2017

18. Image‐guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake.

Author

Yang, Qianlu, Deng, Sisi, Preibsch, Heike, Schade, Tim‐Colin, Koch, André, Berezhnoy, Georgy, Zizmare, Laimdota, Fischer, Anna, Gückel, Brigitte, Staebler, Annette, Hartkopf, Andreas D., Pichler, Bernd J., la Fougère, Christian, Hahn, Markus, Bonzheim, Irina, Nikolaou, Konstantin, and Trautwein, Christoph

Subjects
TRANSCRIPTOMES, BRCA genes, BREAST cancer, THYMIDYLATE synthase, POSITRON emission tomography, TUMOR classification, PROTON magnetic resonance spectroscopy
Abstract

Background: Breast cancer is a metabolically heterogeneous disease, and although the concept of heterogeneous cancer metabolism is known, its precise role in human breast cancer is yet to be fully elucidated. Methods: We investigated in an explorative approach a cohort of 42 primary mamma carcinoma patients with positron emission tomography/magnetic resonance imaging (PET/MR) prior to surgery, followed by histopathology and molecular diagnosis. From a subset of patients, which showed high metabolic heterogeneity based on tracer uptake and pathology classification, tumour centre and periphery specimen tissue samples were further investigated by a targeted breast cancer gene expression panel and quantitative metabolomics by nuclear magnetic resonance (NMR) spectroscopy. All data were analysed in a combinatory approach. Results: [18F]FDG (2‐deoxy‐2‐[fluorine‐18]fluoro‐d‐glucose) tracer uptake confirmed dominance of glucose metabolism in the breast tumour centre, with lower levels in the periphery. Additionally, we observed differences in lipid and proliferation related genes between luminal A and B subtypes in the centre and periphery. Tumour periphery showed elevated acetate levels and enrichment in lipid metabolic pathways genes especially in luminal B. Furthermore, serine was increased in the periphery and higher expression of thymidylate synthase (TYMS) indicated one‐carbon metabolism increased in tumour periphery. The overall metabolic activity based on [18F]FDG uptake of luminal B subtype was higher than that of luminal A and the difference between the periphery and centre increased with tumour grade. Conclusion: Our analysis indicates variations in metabolism among different breast cancer subtypes and sampling locations which details the heterogeneity of the breast tumours. Correlation analysis of [18F]FDG tracer uptake, transcriptome and tumour metabolites like acetate and serine facilitate the search for new candidates for metabolic tracers and permit distinguishing luminal A and B. This knowledge may help to differentiate subtypes preclinically or to provide patients guide for neoadjuvant therapy and optimised surgical protocols based on individual tumour metabolism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Optical Emission Spectroscopy for the Real-Time Identification of Malignant Breast Tissue.

Author

Guergan, Selin, Boeer, Bettina, Fugunt, Regina, Helms, Gisela, Roehm, Carmen, Solomianik, Anna, Neugebauer, Alexander, Nuessle, Daniela, Schuermann, Mirjam, Brunecker, Kristin, Jurjut, Ovidiu, Boehme, Karen A., Dammeier, Sascha, Enderle, Markus D., Bettio, Sabrina, Gonzalez-Menendez, Irene, Staebler, Annette, Brucker, Sara Y., Kraemer, Bernhard, and Wallwiener, Diethelm

Subjects
EMISSION spectroscopy, OPTICAL spectroscopy, BREAST cancer surgery, ELECTROSURGERY, TISSUE differentiation, SURGICAL margin, MAMMAPLASTY
Abstract

Breast conserving resection with free margins is the gold standard treatment for early breast cancer recommended by guidelines worldwide. Therefore, reliable discrimination between normal and malignant tissue at the resection margins is essential. In this study, normal and abnormal tissue samples from breast cancer patients were characterized ex vivo by optical emission spectroscopy (OES) based on ionized atoms and molecules generated during electrosurgical treatment. The aim of the study was to determine spectroscopic features which are typical for healthy and neoplastic breast tissue allowing for future real-time tissue differentiation and margin assessment during breast cancer surgery. A total of 972 spectra generated by electrosurgical sparking on normal and abnormal tissue were used for support vector classifier (SVC) training. Specific spectroscopic features were selected for the classification of tissues in the included breast cancer patients. The average classification accuracy for all patients was 96.9%. Normal and abnormal breast tissue could be differentiated with a mean sensitivity of 94.8%, a specificity of 99.0%, a positive predictive value (PPV) of 99.1% and a negative predictive value (NPV) of 96.1%. For 66.6% patients all classifications reached 100%. Based on this convincing data, a future clinical application of OES-based tissue differentiation in breast cancer surgery seems to be feasible. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. A Cohort of 469 Mayer–Rokitansky–Küster–Hauser Syndrome Patients—Associated Malformations, Syndromes, and Heterogeneity of the Phenotype.

Author

Pietzsch, Martin, Schönfisch, Birgitt, Höller, Alice, Koch, André, Staebler, Annette, Dreser, Katharina, Bettecken, Kristina, Schaak, Lisa, Brucker, Sara Yvonne, and Rall, Katharina

Subjects
HUMAN abnormalities, PHENOTYPES, SKELETAL abnormalities, HETEROGENEITY, SYNDROMES, FIBRODYSPLASIA ossificans progressiva
Abstract

The Mayer–Rokitansky–Küster–Hauser syndrome is characterized by aplasia of the uterus and upper two-thirds of the vagina. While it can appear as an isolated genital malformation, it is often associated with extragenital abnormalities, with little still known about the pathogenetic background. To provide an overview of associated malformations and syndromes as well as to examine possible ties between the rudimentary tissue and patient characteristics, we analyzed a cohort of 469 patients with MRKHS as well as 298 uterine rudiments removed during surgery. A total of 165 of our patients (35.2%) had associated malformations (MRKHS type II). Renal defects were the most common associated malformation followed by skeletal abnormalities. Several patients had atypical associated malformations or combined syndromes. Uterine rudiments were rarer in patients with associated malformations than in patients without them. Rudiment size ranged from 0.3 cm3 to 184.3 cm3 with a mean value of 7.9 cm3. Importantly, MRKHS subtype or concomitant malformations were associated with a different frequency of uterine tissue as well as a different rudiment size and incidence of endometrial tissue, thereby indicating a clear heterogeneity of the phenotype. Further research into the associated molecular pathways and potential differences between MRKHS subtypes is needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)

Author

Singh, Naveena, Hirschowitz, Lynn, Zaino, Richard, Alvarado-Cabrero, Isabel, Duggan, Maire A., Ali-Fehmi, Rouba, Euscher, Elizabeth, Hecht, Jonathan L., Horn, Lars-Christian, Ioffe, Olga, Matias-Guiu, Xavier, McCluggage, W. Glenn, Mikami, Yoshiki, Ordi, Jaume, Parkash, Vinita, Quddus, M. Ruhul, Quick, Charles M., Staebler, Annette, Zaloudek, Charles, Nucci, Marisa, Malpica, Anais, and Oliva, Esther

Published
2019
Full Text
View/download PDF

23. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists

Author

Malpica, Anais, Euscher, Elizabeth D., Hecht, Jonathan L., Ali-Fehmi, Rouba, Quick, Charles M., Singh, Naveena, Horn, Lars-Christian, Alvarado-Cabrero, Isabel, Matias-Guiu, Xavier, Hirschowitz, Lynn, Duggan, Máire, Ordi, Jaume, Parkash, Vinita, Mikami, Yoshiki, Ruhul Quddus, M., Zaino, Richard, Staebler, Annette, Zaloudek, Charles, McCluggage, W. Glenn, and Oliva, Esther

Published
2019
Full Text
View/download PDF

28. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

Author

Block, Matthew S., Vierkant, Robert A., Rambau, Peter F., Winham, Stacey J., Wagner, Philipp, Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G., Taran, Florin Andrei, Sinn, Peter, Sieh, Weiva, Sharma, Raghwa, Rothstein, Joseph H., Cajal, Teresa Ramón y, Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Ness, Roberta B., Nelson, Gregg, Modugno, Francesmary, Menkiszak, Janusz, McGuire, Valerie, McCauley, Bryan M., Mack, Marie, Lubiński, Jan, Longacre, Teri A., Li, Zheng, Lester, Jenny, Kennedy, Catherine J., Kalli, Kimberly R., Jung, Audrey Y., Johnatty, Sharon E., Jimenez-Linan, Mercedes, Jensen, Allan, Intermaggio, Maria P., Hung, Jillian, Herpel, Esther, Hernandez, Brenda Y., Hartkopf, Andreas D., Harnett, Paul R., Ghatage, Prafull, García-Bueno, José M., Gao, Bo, Fereday, Sian, Eilber, Ursula, Edwards, Robert P., de Sousa, Christiani B., de Andrade, Jurandyr M., Chudecka-Głaz, Anita, Chenevix-Trench, Georgia, Cazorla, Alicia, Brucker, Sara Y., Alsop, Jennifer, Whittemore, Alice S., Steed, Helen, Staebler, Annette, Moysich, Kirsten B., Menon, Usha, Koziak, Jennifer M., Kommoss, Stefan, Kjaer, Susanne K., Kelemen, Linda E., Karlan, Beth Y., Huntsman, David G., Hφgdall, Estrid, Gronwald, Jacek, Goodman, Marc T., Gilks, Blake, García, María José, Fasching, Peter A., de Fazio, Anna, Deen, Suha, Chang-Claude, Jenny, Candido dos Reis, Francisco J., Campbell, Ian G., Brenton, James D., Bowtell, David D., Benítez, Javier, Pharoah, Paul D.P., Köbel, Martin, Ramus, Susan J., Goode, Ellen L., Bowtell, D., Chenevix-Trench, G., Green, A., Webb, P., DeFazio, A., Gertig, D., Traficante, N., Fereday, S., Moore, S., Hung, J., Harrap, K., Sadkowsky, T., Pandeya, N., Malt, M., Mellon, A., Robertson, R., Bergh, Vanden T., Jones, M., Mackenzie, P., Maidens, J., Nattress, K., Chiew, Y. E., Stenlake, A., Sullivan, H., Alexander, B., Ashover, P., Brown, S., Corrish, T., Green, L., Jackman, L., Ferguson, K., Martin, K., Martyn, A., Ranieri, B., White, J., Jayde, V., Mamers, P., Bowes, L., Galletta, L., Giles, D., Hendley, J., Alsop, K., Schmidt, T., Shirley, H., Ball, C., Young, C., Viduka, S., Tran, Hoa, Bilic, Sanela, Glavinas, Lydia, Brooks, Julia, Stuart-Harris, R., Kirsten, F., Rutovitz, J., Clingan, P., Glasgow, A., Proietto, A., Braye, S., Otton, G., Shannon, J., Bonaventura, T., Stewart, J., Begbie, S., Friedlander, M., Bell, D., Baron-Hay, S., Ferrier, A., Gard, G., Nevell, D., Pavlakis, N., Valmadre, S., Young, B., Camaris, C., Crouch, R., Edwards, L., Hacker, N., Marsden, D., Robertson, G., Beale, P., Beith, J., Carter, J., Dalrymple, C., Houghton, R., Russell, P., Links, M., Grygiel, J., Hill, J., Brand, A., Byth, K., Jaworski, R., Harnett, P., Sharma, R., Wain, G., Ward, B., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Obermair, A., Perrin, L., Wyld, D., Nicklin, J., Davy, M., Oehler, M. K., Hall, C., Dodd, T., Healy, T., Pittman, K., Henderson, D., Miller, J., Pierdes, J., Blomfield, P., Challis, D., McIntosh, R., Parker, A., Brown, B., Rome, R., Allen, D., Grant, P., Hyde, S., Laurie, R., Robbie, M., Healy, D., Jobling, T., Manolitsas, T., McNealage, J., Rogers, P., Susil, B., Sumithran, E., Simpson, I., Phillips, K., Rischin, D., Fox, S., Johnson, D., Lade, S., Loughrey, M., OʼCallaghan, N., Murray, W., Waring, P., Billson, V., Pyman, J., Neesham, D., Quinn, M., Underhill, C., Bell, R., Ng, L. F., Blum, R., Ganju, V., Hammond, I., Leung, Y., McCartney, A., Buck, M., Haviv, I., Purdie, D., Whiteman, D., and Zeps, N.

Published
2018
Full Text
View/download PDF

29. Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center.

Author

Taran, Florin Andrei, Pasternak, Jana, Staebler, Annette, Rohner, Annika, Neis, Felix, Engler, Tobias, Oberlechner, Ernst, Schönfisch, Birgitt, Juhasz-Böss, Ingolf, Hartkopf, Andreas Daniel, Brucker, Sara, and Walter, Christina Barbara

Subjects
EPITHELIAL cell tumors, PATIENT aftercare, CONFIDENCE intervals, MULTIVARIATE analysis, VULVAR tumors, RETROSPECTIVE studies, SURGICAL margin, DISEASE relapse, DESCRIPTIVE statistics, PROGRESSION-free survival, OVERALL survival, DISEASE risk factors, EVALUATION
Abstract

Simple Summary: Squamous cell cancer (SCC) of the vulva is one of the rare gynecological malignancies, and surgery is the initial treatment of choice for early-stage vulvar cancer. International guidelines offer conflicting recommendations regarding surgical and pathological tumor-free resection margins for SCC of the vulva. The aim of this study was therefore to analyze the node-negative patients with SCC of the vulva treated with surgery alone at the Department of Women's Health, University Clinic, Tuebingen, Germany with regard to the achieved marginal distance and its impact on prognosis. The present study observed no significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva on disease-free and overall survival. Background: The aim of this study was to evaluate the impact of pathological tumor-free margin distance on survival in SCC patients treated with surgery alone. Methods: This retrospective study included 128 patients with node-negative disease that received no adjuvant treatment. Disease-free and overall survival were analyzed according to pathological tumor-free margin distance. Results: The patients were subclassified into three resection margin category groups: "1 to 3 mm" (n = 42), ">3 to 8 mm" (n = 47) or ">8 mm" (n = 39). Thirty-nine of the 128 patients (30.5%) developed recurrent disease. Median follow-up for disease-free survival (DFS) was 6.49 years (95% CI 5.16 years; 7.62 years), and median follow-up for overall survival (OS) was 6.29 years (95% CI 5.45 years; 7.33 years). The 5-year DFS rate was 0.70 (95% CI: 0.62–0.79), and the 5-year OS rate was 0.79 (95% CI: 0.71–0.87). Regarding the survival outcome, there were no independent significant differences in either disease-free survival (DFS) (p = 0.300) or overall survival (p = 1.000) among patients within the three tumor-free resection margin categories. Multivariate analyses did not show any statistically significant association between tumor-free resection margin distance and recurrent disease or death, either when analyzed as a categorical variable or when analyzed as a continuous variable. Conclusion: The present study did not show a significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva (that did not receive adjuvant treatment) on disease-free and overall survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Treatment and survival of patients with malignant ovarian sex cord‐stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database.

Author

Klar, Maximilian, Plett, Helmut, Harter, Philipp, Heitz, Florian, Kommoss, Stefan, Hartkopf, Andreas Daniel, Grube, Marcel, Roser, Eva, Sehouli, Jalid, Braicu, Iona, Czogalla, Bastian, Burges, Alexander, Bossart, Michaela, Hasanov, Mir Fuad, Link, Teresa, Staebler, Annette, Mayr, Doris, Buderath, Paul, and Hasenburg, Annette

Published
2023
Full Text
View/download PDF

31. Consensus based recommendations for the diagnosis of serous tubal intraepithelial carcinoma: an international Delphi study.

Author

Bogaerts, Joep M A, van Bommel, Majke H D, Hermens, Rosella P M G, Steenbeek, Miranda P, de Hullu, Joanne A, van der Laak, Jeroen A W M, Shih, Ie‐Ming, McCluggage, W Glenn, Gilks, C Blake, Carlson, Joseph W, Rabban, Joseph T, Ewing‐Graham, Patricia C, Killeen, Jeffrey L, Lastra, Ricardo, Parkash, Vinita, O'Riain, Ciaran, Staebler, Annette, Vang, Russell, Bulten, Johan, and vd Vijver, Koen K

Subjects
CARCINOMA, LIKERT scale, DIAGNOSIS, PATHOLOGISTS
Abstract

Aim: Reliably diagnosing or safely excluding serous tubal intraepithelial carcinoma (STIC), a precursor lesion of tubo‐ovarian high‐grade serous carcinoma (HGSC), is crucial for individual patient care, for better understanding the oncogenesis of HGSC, and for safely investigating novel strategies to prevent tubo‐ovarian carcinoma. To optimize STIC diagnosis and increase its reproducibility, we set up a three‐round Delphi study. Methods and results: In round 1, an international expert panel of 34 gynecologic pathologists, from 11 countries, was assembled to provide input regarding STIC diagnosis, which was used to develop a set of statements. In round 2, the panel rated their level of agreement with those statements on a 9‐point Likert scale. In round 3, statements without previous consensus were rated again by the panel while anonymously disclosing the responses of the other panel members. Finally, each expert was asked to approve or disapprove the complete set of consensus statements. The panel indicated their level of agreement with 64 statements. A total of 27 statements (42%) reached consensus after three rounds. These statements reflect the entire diagnostic work‐up for pathologists, regarding processing and macroscopy (three statements); microscopy (eight statements); immunohistochemistry (nine statements); interpretation and reporting (four statements); and miscellaneous (three statements). The final set of consensus statements was approved by 85%. Conclusion: This study provides an overview of current clinical practice regarding STIC diagnosis amongst expert gynecopathologists. The experts' consensus statements form the basis for a set of recommendations, which may help towards more consistent STIC diagnosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A platform of patient-derived microtumors identifies individual treatment responses and therapeutic vulnerabilities in ovarian cancer

Author

Anderle, Nicole, Koch, André, Gierke, Berthold, Keller, Anna-Lena, Staebler, Annette, Hartkopf, Andreas, Brucker, Sara Y., Pawlak, Michael, Schenke-Layland, Katja, Schmees, Christian, Di Renzo, Maria Flavia, and Corso, Simona

Subjects
Proteomics, Cancer Research, Ovarian neoplasms, Drug therapy, cancer immunotherapy, Proteomanalyse, anti-cancer drug sensitivity, Protein array analysis, RPPA protein profiling, patient-derived tumor model, Immuntherapie, ovarian cancer, Oncology, Eierstockkrebs, ddc:610, Immunotherapy, Chemotherapie, DDC 610 / Medicine & health
Abstract

Simple Summary For personalized oncology, it is crucial to develop appropriate patient-derived tumor models that allow individualized validation of the most effective cancer therapy. The objective of this study was to develop and characterize a new patient-derived ovarian cancer tumor model composed of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TIL). In contrast to other preclinical tumor models, such as patient-derived organoids, PDM are generated within 24 h from fresh ovarian tumor samples. From immunohistochemical comparison with the original primary tumor, we conclude that the histopathological features of the original tumor are essentially preserved. Importantly, we successfully identified treatment-sensitive and treatment-resistant tumor models for standard platinum-based therapy by reverse-phase protein array (RPPA) analysis of PDM. Furthermore, we were able to evaluate the efficacy of cancer immunotherapy by co-culturing PDM and autologous TILs. PDM and TILs may therefore serve as a preclinical platform to identify individualized, tailored cancer treatments in the future. Abstract In light of the frequent development of therapeutic resistance in cancer treatment, there is a strong need for personalized model systems representing patient tumor heterogeneity, while enabling parallel drug testing and identification of appropriate treatment responses in individual patients. Using ovarian cancer as a prime example of a heterogeneous tumor disease, we developed a 3D preclinical tumor model comprised of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TILs) to identify individual treatment vulnerabilities and validate chemo-, immuno- and targeted therapy efficacies. Enzymatic digestion of primary ovarian cancer tissue and cultivation in defined serum-free media allowed rapid and efficient recovery of PDM, while preserving histopathological features of corresponding patient tumor tissue. Reverse-phase protein array (RPPA)-analyses of >110 total and phospho-proteins enabled the identification of patient-specific sensitivities to standard, platinum-based therapy and thereby the prediction of potential treatment-responders. Co-cultures of PDM and autologous TILs for individual efficacy testing of immune checkpoint inhibitor treatment demonstrated patient-specific enhancement of cytotoxic TIL activity by this therapeutic approach. Combining protein pathway analysis and drug efficacy testing of PDM enables drug mode-of-action analyses and therapeutic sensitivity prediction within a clinically relevant time frame after surgery. Follow-up studies in larger cohorts are currently under way to further evaluate the applicability of this platform to support clinical decision making., publishedVersion

Published
2022

37. Noninvasive Physical Plasma as Innovative and Tissue-Preserving Therapy for Women Positive for Cervical Intraepithelial Neoplasia

Author

Marzi, Julia, Stope, Matthias B., Henes, Melanie, Koch, André, Wenzel, Thomas, Holl, Myriam, Layland, Shannon L., Neis, Felix, Bösmüller, Hans, Ruoff, Felix, Templin, Markus, Krämer, Bernhard, Staebler, Annette, Barz, Jakob Philipp, Carvajal Berrio, Daniel A., Enderle, Markus, Loskill, Peter M., Brucker, Sara Y., Schenke-Layland, Katja, Weiss, Martin, and Publica

Subjects
physical atmospheric pressure plasma, low- and high-grade squamous intraepithelial lesions (LSILs and HSILs), Raman imaging, cervical intraepithelial neoplasia (CIN), clinical plasma application
Abstract

(1) Background: Cervical intraepithelial neoplasia (CIN) of long-term persistence or associated with individual treatment indications often requires highly invasive treatments. These are associated with risks of bleeding, infertility, and pregnancy complications. For low- and middle-income countries (LMICs), standard treatment procedures are difficult to implement and manage. We characterized the application of the highly energized gas "noninvasive physical plasma" (NIPP) for tissue devitalization and the treatment of CIN. (2) Methods: We report the establishment of a promising tissue devitalization procedure by NIPP application. The procedure was characterized at the in vitro, ex vivo and in vivo levels. We performed the first prospective, single-armed phase-IIb trial in 20 CIN1/2 patients (NCT03218436). (3) Results: NIPP-treated cervical cancer cells used as dysplastic in vitro model exhibited significant cell growth retardation due to DNA damage, cell cycle arrest and apoptosis. Ex vivo and in vivo tissue assessments showed a highly noninvasive and tissue-preserving treatment procedure which induces transmucosal tissue devitalization. Twenty participants were treated with NIPP and attended a 24-week follow-up. Treatment success was achieved in 19 (95%) participants without postinterventional complications other than mild to moderate discomfort during application. (4) Conclusions: The results from this study preliminarily suggest that NIPP could be used for an effective and tissue-preserving treatment for CIN without the disadvantages of standard treatments. However, randomized controlled trials must confirm the efficacy and noninferiority of NIPP compared to standard treatments.

Published
2022

40. Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary

Author

Pilsworth, Jessica A., Cochrane, Dawn R., Xia, Zhouchunyang, Aubert, Geraldine, Färkkilä, Anniina E. M., Horlings, Hugo M., Yanagida, Satoshi, Yang, Winnie, Lim, Jamie L. P., Wang, Yi Kan, Bashashati, Ali, Keul, Jacqueline, Wong, Adele, Norris, Kevin, Brucker, Sara Y., Taran, Florin-Andrei, Krämer, Bernhard, Staebler, Annette, van Meurs, Hannah, Oliva, Esther, Shah, Sohrab P., Kommoss, Stefan, Kommoss, Friedrich, Gilks, C. Blake, Baird, Duncan M., and Huntsman, David G.

Published
2019
Full Text
View/download PDF

41. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Author

Goode, Ellen L., Block, Matthew S., Kalli, Kimberly R., Vierkant, Robert A., Chen, Wenqian, Fogarty, Zachary C., Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L., Jensen, Allan, Osorio, Ana, Hartkopf, Andreas D., Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M., Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y., Fridley, Brooke L., McCauley, Bryan M., Kennedy, Catherine J., Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B., Tiezzi, Daniel G., Wachter, David L., Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H., Kelley, Joseph L., de Andrade, Jurandyr M., Robles-Díaz, Luis, Intermaggio, Maria P., Widschwendter, Martin, Beckmann, Matthias W., Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R., Rambau, Peter F., Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P., Ness, Roberta B., Orsulic, Sandra, Brucker, Sara Y., Johnatty, Sharon E., Longacre, Teri A., Eilber, Ursula, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S., deFazio, Anna, Staebler, Annette, Karlan, Beth Y., Gilks, Blake, Bowtell, David D., Høgdall, Estrid, Candido dos Reis, Francisco J., Steed, Helen, Campbell, Ian G., Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M., Chang-Claude, Jenny, Moysich, Kirsten B., Kelemen, Linda E., Cook, Linda S., Goodman, Marc T., García, María José, Fasching, Peter A., Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K., Menon, Usha, Brenton, James D., Pharoah, Paul D. P., Chenevix-Trench, Georgia, Huntsman, David G., Winham, Stacey J., Köbel, Martin, and Ramus, Susan J.

Published
2017
Full Text
View/download PDF

42. Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer

Author

Pérez-Gómez, Eduardo, Andradas, Clara, Blasco-Benito, Sandra, Caffarel, María M., García-Taboada, Elena, Villa-Morales, María, Moreno, Estefanía, Hamann, Sigrid, Martín-Villar, Ester, Flores, Juana M., Wenners, Antonia, Alkatout, Ibrahim, Klapper, Wolfram, Röcken, Christoph, Bronsert, Peter, Stickeler, Elmar, Staebler, Annette, Bauer, Maret, Arnold, Norbert, Soriano, Joaquim, Pérez-Martínez, Manuel, Megías, Diego, Moreno-Bueno, Gema, Ortega-Gutiérrez, Silvia, Artola, Marta, Vázquez-Villa, Henar, Quintanilla, Miguel, Fernández-Piqueras, José, Canela, Enric I., McCormick, Peter J., Guzmán, Manuel, and Sánchez, Cristina

Published
2015
Full Text
View/download PDF

46. Recurrence Score ® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial.

Author

Dannehl, Dominik, Engler, Tobias, Volmer, Lea L., Staebler, Annette, Fischer, Anna K., Weiss, Martin, Hahn, Markus, Walter, Christina B., Grischke, Eva-Maria, Fend, Falko, Taran, Florin-Andrei, Brucker, Sara Y., and Hartkopf, Andreas D.

Subjects
ADJUVANT chemotherapy, ONCOGENES, CANCER relapse, INDIVIDUALIZED medicine, GENE expression, DECISION making in clinical medicine, BIOLOGICAL assay, COMBINED modality therapy, TUMOR markers, HORMONE receptor positive breast cancer
Abstract

Simple Summary: Hormone receptor-positive (HR+), HER2-negative (HER2−) is the most common breast cancer subtype (approximately 75% of all breast cancer cases). Adjuvant chemotherapy can be administered to patients that undergo operative tumor removal with only few metastatic axillary lymph nodes (0–3). However, using classical risk biomarkers to guide adjuvant chemotherapy recommendation leads to overtreatment of patients including unnecessary possible chemotherapy-related toxicities. This prospective study assessed whether the multigene-expression assay Oncotype DX® that has been validated in two large clinical phase III trials, effectively reduces adjuvant chemotherapy recommendation in a real-world setting. This study could demonstrate that absolute adjuvant chemotherapy recommendation can be reduced by nearly 15% using Oncotype DX®. Furthermore, this study could show that the Oncotype DX® recurrence score correlates to classic biomarkers that are commonly used to classify the aggressiveness of breast cancer. Background: Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) early breast cancer (eBC) with a high risk of relapse often undergo adjuvant chemotherapy. However, only a few patients will gain benefit from chemotherapy. Since classical tumor characteristics (grade, tumor size, lymph node involvement, and Ki67) are of limited value to predict chemotherapy efficacy, multigene expression assays such as the Oncotype DX® test were developed to reduce over- and undertreatment. The IRMA trial analyzed the impact of Recurrence Score® (RS) assessment on adjuvant treatment recommendations. Materials and methods: The RS result was assessed in patients with HR+/HER2− unilateral eBC with 0–3 pathologic lymph nodes who underwent primary surgical treatment at the Department for Women's Health of Tuebingen University, Germany. Therapy recommendations without knowledge of the RS result were compared to therapy recommendations with awareness of the RS result. Results: In total, 245 patients underwent RS assessment. Without knowledge of the RS result, 92/245 patients (37.6%) would have been advised to receive chemotherapy. After RS assessment, 56/245 patients (22.9%) were advised to undergo chemotherapy. Chemotherapy was waived in 47/92 patients (51.1%) that were initially recommended to receive it. Chemotherapy was added in 11/153 patients (7.2%) that were recommended to not receive it initially. Summary: Using the RS result to guide adjuvant treatment decisions in HR+/HER2− breast cancer led to a substantial reduction of chemotherapy. In view of the results achieved in prospective studies, the RS result is among other risk-factors suitable for the individualization of adjuvant systemic therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome.

Author

Ruoff, Felix, Kersten, Nicolas, Anderle, Nicole, Jerbi, Sandra, Stahl, Aaron, Koch, André, Staebler, Annette, Hartkopf, Andreas, Brucker, Sara Y., Hahn, Markus, Schenke-Layland, Katja, Schmees, Christian, and Templin, Markus F.

Subjects
PROTEINS, EVALUATION of medical care, STATISTICS, LOG-rank test, RETROSPECTIVE studies, MANN Whitney U Test, GENE expression profiling, DESCRIPTIVE statistics, KAPLAN-Meier estimator, CHI-squared test, TUMOR markers, DATA analysis software, DATA analysis, BREAST tumors, IMMUNOTHERAPY, LONGITUDINAL method
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results